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(57)	 ABSTRACT
The present disclosure provides ex vivo-derived mineralized
three-dimensional bone constructs. The bone constructs are
obtained by culturing osteoblasts and osteoclast precursors
under randomized gravity vector conditions. Preferably, the
randomized gravity vector conditions are obtained using a
low shear stress rotating bioreactor, such as a High Aspect
Ratio Vessel (HARV) culture system. The bone constructs of
the disclosure have utility in physiological studies of bone
formation and bone function, in drug discovery, and in ortho-
pedics.
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MINERALIZED THREE -DIMENSIONAL	 SUMMARY
BONE CONSTRUCTS
This application claims the benefit of U.S. Provisional
Patent Application Ser. No. 60/787,431, filed Mar. 30, 2006,
specifically incorporated herein by reference in its entirety.
The U.S. Government has a paid-up license in this inven-
tion and the right in limited circumstances to require the
patent owners to license others on reasonable terms as pro-
vided for by the terms of Contract No. NNJ04HF46H
awarded by the National Aeronautics and Space Administra-
tion (NASA).
FIELD OF THE INVENTION
The invention relates to ex vivo-derived mineralized three-
dimensional bone constructs which replicate natural bone.
BACKGROUND
One of the central problems associated with studying both
the normal and pathophysiology of bone is that as an organ
system it is slow growing and the time to show an observable
response to a particular stimulus is relatively long. The nature
of the mineralized tissue matrix of bone in vivo and its com-
plex architecture also presents several technical problems
associated with how experimental observations can be made.
At present, truly informative studies designed to understand
bone physiology have relied primarily on the removal of
samples of bone tissue from normal or diseased tissue either
in a clinical setting or from experimental animal models.
To date, there is no three dimensional tissue culture model
of bone, either of animal or human origin. The prior art has
relied primarily on the use of monotype cell type cultures of
osteoblasts or osteoclast cells grown on planar, two dimen-
sional tissue culture surfaces. Such cultures have also been
grown in three dimensional collagen support gels and some
investigators have utilized culture systems that allow types of
mechanical strain to be applied to the cells in order to study
the effects of mechanical loading. However, these cultures
have been primarily focused on the responses of a single cell
type, such as osteoblasts, to various environmental stimuli.
Existing planar monotype tissue culture models of bone do
not allow the study of the interactions between the different
cell types present in normal bone responsible for normal bone
remodeling. The developmentally inactive osteocyte cell type
present in the mineralized matrix of normal bone in vivo
(from which osteoblasts are derived) have yet to be fully
characterized in any tissue culture model due to their sup-
posed transformation into osteoblasts once they have been
removed from the bone matrix and placed into culture.
Moreover, the process of mineralization, which is essential
to the formation of new bone, has previously only been stud-
ied in monotype cultures of osteoblasts. The mineralization
process has been studied in such models in the absence of the
major cell type involved in the removal of mineralized mate-
rial, namely the osteoclast. However, the complex interplay
between both of these cell types is essential for normal bone
remodeling (i.e. bone formation and bone loss). Without both
cell types being present, a true in vitro/ex vivo representation
of the normal or indeed pathological processes involved in the
bone remodeling process is impossible. As such, the use of
such monotype culture models to investigate the effects of
manipulations, such as anti -o steoporetic drugs or mechanical
load interventions, have limited utility due to the lack of
similarity to the true physiological state existing within bone
tissue in vivo.
In one aspect, the disclosure provides ex vivo-derived min-
eralized three-dimensional bone constructs, each comprising
5 a spheroid of between about 200 µm and about 4 mm in
diameter having an outer layer surrounding an inner core. The
outer layer is comprised of osteoclasts, and the inner layer is
comprised of osteoblasts, osteocytes, or both osteoblasts and
osteocytes embedded within a crystalline matrix. The crys-
io talline matrix is comprised of calcium, phosphates, and car-
bonates.
In another aspect, the disclosure provides methods for pro-
ducing mineralized three-dimensional bone constructs. In
one embodiment, a method comprises introducing osteoclast
15 precursors and osteoblasts into a culture vessel comprising a
matrix-free culture medium; culturing the osteoclast precur-
sors and the osteoblasts under randomized gravity vector
conditions wherein aggregates of the osteoblasts and the
osteoclast precursors are formed; and introducing a matrix-
20 free mineralization culture medium into the culture vessel
and culturing the aggregates under randomized gravity vector
conditions.
In another embodiment, a method comprises culturing
osteoclast precursors and osteoblasts in a matrix-free culture
25 medium using a low shear rotational three-dimensional tissue
culture technique under conditions effective to form aggre-
gates comprising the osteoblasts and the osteoclast precur-
sors, and culturing the aggregates using said low shear rota-
tional three-dimensional tissue culture technique in a matrix-
30 free mineralization culture medium that promotes
mineralization of said aggregates.
In another embodiment, a method comprises introducing
osteoclast precursors and osteoblasts into a cylindrical cul-
ture vessel that rotates about a substantially central horizontal
35 axis, the cylindrical culture vessel comprising a matrix-free
culture medium; culturing the osteoblasts and the osteoclast
precursors in the cylindrical culture vessel during substan-
tially horizontal rotation at a rate effective to create low shear
conditions and to promote the formation of aggregates com-
40 prising the osteoclast precursors and said osteoblasts; and
introducing a matrix-free mineralization culture medium into
the cylindrical culture vessel and culturing the aggregates
during substantially horizontal rotation at a rate effective to
create low shear conditions.
45 In another embodiment, the method comprises introducing
osteoclast precursors and osteoblasts into a cylindrical cul-
ture vessel that rotates about a substantially central horizontal
axis, the cylindrical culture vessel comprising a matrix-free
culture medium; culturing the osteoblasts and the osteoclast
50 precursors in the cylindrical culture vessel during substan-
tially horizontal rotation at a rate effective to create low shear
conditions and to promote the formation of aggregates com-
prising the osteoclast precursors and said osteoblasts; further
culturing the aggregates in the cylindrical culture vessel dur-
55 ing substantially horizontal rotation at a rate effective to cre-
ate low shear conditions so that the aggregates grow in size
and the osteoclast precursors differentiate into osteoclasts;
and introducing a matrix-free mineralization culture medium
into the cylindrical culture vessel and culturing the aggregates
6o during substantially horizontal rotation at a rate effective to
create low shear conditions, wherein the mineralized three-
dimensional bone constructs are formed.
In another aspect, the disclosure provides a mineralized
three-dimensional bone construct produced by introducing
65 osteoclast precursors and osteoblasts into a cylindrical cul-
ture vessel that rotates about a substantially central horizontal
axis, the cylindrical culture vessel comprising a matrix-free
US 8,076,136 B2
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culture medium; culturing the osteoblasts and the osteoclast
precursors in the cylindrical culture vessel during substan-
tially horizontal rotation at a rate effective to create low shear
conditions and to promote the formation of aggregates com-
prising the osteoclast precursors and said osteoblasts; further
culturing the aggregates in the cylindrical culture vessel dur-
ing substantially horizontal rotation at a rate effective to cre-
ate low shear conditions so that the aggregates grow in size
and the osteoclast precursors differentiate into osteoclasts;
and introducing a matrix-free mineralization culture medium
into the cylindrical culture vessel and culturing the aggregates
during substantially horizontal rotation at a rate effective to
create low shear conditions, wherein the mineralized three-
dimensional bone constructs are formed.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a flowchart of an example of a method for pre-
paring mineralized three-dimensional bone constructs.
FIGS. 2A-213 present images of mineralized three-dimen-
sional bone constructs at 14 days of mineralization (FIG. 2A)
and 21 days of mineralization (FIG. 213). The scale bars each
represent I cm.
FIGS. 3A-313 present images of mineralized three-dimen-
sional bone constructs. FIG. 3A presents a fluorescence con-
focal microscopy image of an optical section through bone
constructs in which the osteoclast precursor cells were
labeled with a fluorescent cell tracking dye (observable as
white spots in FIG. 3A). FIG. 3B shows the same constructs
viewed in incident laser light (i.e. non-fluorescent illumina-
tion) to illustrate the shape of the constructs. The scale bar in
each of FIG. 3A and FIG. 3B is 200 µm.
FIG. 4 presents a three dimensional reconstruction of a
large bone construct using Z series confocal imaging. Osteo-
clast precursors were labeled with a fluroescent cell tracking
dye. Panels A-I in FIG. 4 are the individual images usedby the
confocal imaging software to build the optical reconstruction
of the bone construct in three dimensions, each image repre-
senting a sequential view over the surface of the construct
(white spots indicate individual cells).
FIGS. 5A-5D show Alizarin red S staining and von Kossa
staining of sections through a bone construct. FIG. 5A shows
a 5x magnification image of Alizarin red S staining and FIG.
5B shows a 20x magnification image of Alizarin red S stain-
ing (which appears as the dark regions of the images). FIG.
5C shows a 5x magnification image of von Kossa staining and
FIG. 5B shows a 20x magnification image of von Kossa
staining (which appears as the dark regions of the images).
FIGS. 6A-613 show Harris Hematoxylin staining of sec-
tions through a bone construct. FIG. 6A is a 5x magnification
image and FIG. 6B is a 20x magnification image. The dark
regions of the image indicate staining. Arrows in FIG. 6B
point to large numbers of cells embedded within the crystal-
line matrix in the three dimensional construct.
FIGS. 7A-7C show images of bone construct in which
osteoclast precursors were labeled with a fluorescent cell
tracking dye prior to formation of the bone construct, and the
bone construct was stained with a primary antibody against
osteocalcein (a marker of osteoclast differentiation) and an
Alexa 488-labeled secondary antibody. FIG. 7A shows osteo-
calcein staining, FIG. 7B shows CellTracker-Orange stain-
ing, and FIG. 7C shows the same construct illuminated with
incident laser light. The results indicate that osteocalcein
staining and cell tracking dye (both visible as a white "ring"
In one aspect, the present disclosure provides mineralized
three-dimensional bone constructs (sometimes referred to
herein simply as "bone constructs"). The mineralized three
dimensional constructs of the disclosure are "bone like" in
io appearance by visual inspection, in certain important respects
resembling trabecular bone (also known in the art as "spongy
bone"). In preferred embodiments, the mineralized three-
dimensional bone constructs of the disclosure are macro-
scopic in size and are approximately spheroidal in shape,
15 preferably between about 200 µm and about 4 mm in diam-
eter; however, larger and smaller bone constructs are specifi-
cally contemplated.
The bone constructs comprise an inner core surrounded by
an outer layer. The inner core comprises a three-dimensional
20 crystalline matrix that stains positively with Alizarin Red S
stain and with the von Kossa histochemical stain, indicating
that it comprises mineral elements observed in normal human
bone in vivo, including calcium, phosphates, and carbonates.
The inner core also comprises osteoblasts and/or osteocytes
25 embedded within the crystalline matrix, and is preferably
devoid of necrotic tissue. Osteocytes are developmentally
inactive cells found only in native bone tissue in vivo and are
believed to be formed from osteoblasts that have become
trapped in the crystalline matrix. The outer layer is comprised
30 of osteoclasts, which may express the differentiation marker
osteocalcein. The cell types in the bone constructs of the
disclosure can be obtained from any mammalian species, but
are preferably obtained from humans.
In another aspect, the disclosure provides methods for pro-
s y ducing the mineralized three-dimensional bone constructs. In
general, the bone constructs of the disclosure are produced by
culturing osteoclast precursors and osteoblasts together under
randomized gravity vector conditions (approaching those
conditions that cultured cells experience during microgravity
40 culture) in a matrix-free culture medium. Osteoclast precur-
sors may be obtained from bone marrow and/or peripheral
blood lymphocytes by techniques well known in the art.
Osteoclast precursors may also be obtained from commercial
sources (for example, from Cambrex/Loma, Inc.). Osteo-
45 blasts, preferably primary human osteoblasts, may also be
obtained by techniques well known in the art, and may also be
obtained from commercial sources (for example, from Pro-
moCell, Inc. and from Cambrex/Loma, Inc.). A "matrix-free
culture medium" is a cell culture medium which does not
50 include carrier material (such as microcarrier beads or col-
lagen gels) onto which osteoblasts and osteoclast precursors
can attach. Suitable cell culture media include Eagle's Mini-
mal Essential Medium (EMEM) or Dulbecco's Modified
Eagle's Medium (DMEM), preferably supplemented with
55 fetal bovine serum (FBS). Preferably, the matrix-free culture
medium also comprises osteoblast growth supplements such
as ascorbic acid. The matrix-free culture medium preferably
also further comprises osteoclast differentiation factors, such
as Receptor Activator of NF-kB (RANK) ligand and mac-
ho rophage colony stimulating factor (M-CSF). For example, in
one embodiment the matrix-free culture medium comprises
FBS-supplemented DMEM, ascorbic acid, RANK ligand,
and M-CSF. Example 2 includes a description of one suitable
matrix-free culture medium.
65 The osteoclast precursors and the osteoblasts are cultured
together under randomized gravity vector conditions effec-
tive to achieve the formation of mixed aggregates of the two
4
around the construct in FIGS. 7A and 713) are spatially local-
ized to the same area of the construct.
DETAILED DESCRIPTION
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cell types. The aggregates are then further cultured under	 drical culture vessels are often referred to in the art as Slow
randomized gravity vector conditions to increase the aggre- 	 Turning Lateral Vessels (STLVs). STLVs typically have a
gates size and to differentiate the osteoclast precursors into 	 core, comprised of a gas permeable membrane, running
mature osteoclasts.	 through the center of the cylinder in order to allow gas
After a predetermined time, the aggregates are cultured 5 exchange between the culture medium and the surrounding
under randomized gravity vector conditions in a matrix-free 	 incubator environment. STLVs are available from Synthecon,
mineralization culture medium. A "matrix-free mineraliza-	 Inc.
tion culture medium" is a cell culture medium that includes 	 The use of low shear stressing rotating bioreactor culture
one or more mineralization agents, such as osteoblast differ- 	 systems is described in, for example, Nickerson et al., Immu-
entiation factors, that induce osteoblasts to produce crystal-  io nity. 69:7106-7120 (2001); Carterson et al., Infection &
line deposits (comprising calcium, phosphate, and carbon-	 Immunity. 73(2):1129-40 (2005); and in Goodwin et al. U.S.
ates) but which does not include carrier material (such as	 Pat. No. 5,496,722, each of which is specifically incorporated
microcarrierbeads and collagen gels) onto which osteoblasts 	 herein by reference in its entirety.
and osteoclast precursors can attach. For example, in one	 In one embodiment, osteoclast precursors and osteoblasts
embodiment, a matrix-free mineralization culture medium 15 are introduced into a cylindrical culture vessel in matrix-free
comprises FBS-supplemented EMEM or DMEM, supple- 	 culture medium. The osteoclast precursors and the osteo-
mented with the osteoblast differentiation factors. Osteoblast 	 blasts may be introduced into the cylindrical culture vessel
differentiation factors include beta-glycerophosphate and 	 separately, or they may be introduced into the cylindrical
hydrocortisone-21-hemisuccinate. Preferably, the matrix- 	 culture vessel as a pre-mixture of the two cell types. Prefer-
free mineralization culture medium also includes osteoclast 2o ably, the cells are introduced into the cylindrical culture ves-
differentiation factors such as RANK ligand and M-CSF, and	 sel at a osteoblastosteoclast precursor ratio of from about 2:1
also includes osteoblast growth supplements such as ascorbic	 to about 3:1, although higher and lower ratios are within the
acid. For example, in one embodiment the matrix-free min-	 scope of the disclosure. The absolute number of cells intro-
eralization culture medium comprises FB S -supplemented
	
duced into the cylindrical culture vessel may also be varied.
DMEM, beta-glycerophosphate, ascorbic acid, hydrocorti- 25 For example, in some embodiments where a ratio of about 2:1
sone-21-hemisuccinate, RANK ligand and M-CSF. Example	 is employed, about 2 million osteoblasts and about 1 million
2 includes a description of one suitable matrix-free mineral-	 osteoclast precursors are introduced; in other embodiments
ization medium.	 about 4 million osteoblasts and about 2 million osteoclast
In preferred embodiments, randomized gravity vector con-	 precursors are introduced; and in still further embodiments
ditions are obtained by culturing osteoclast precursors and 3o about 8 million osteoblasts and about 4 million osteoclast
osteoblasts in a low shear stress rotating bioreactor. Such	 precursors are introduced. The ratio of osteoblasts:osteoclast
bioreactors were initially designed to mimic some of the	 precursors and the absolute number of cells can be varied in
physical conditions experienced by cells cultured in true	 order to vary the size and the number of aggregates formed. In
microgravity during space flight. In general, a low shear stress 	 addition, other cell types may also be introduced into the
rotating bioreactor comprises a cylindrical culture vessel. 35 cylindrical culture vessel. For example, bone marrow stroma
One or more ports are operatively associated with the lumen 	 and stem cells may be cultured along with the osteoblasts and
of the vessel for the introduction and removal of cells and	 the osteoclast precursors.
culture media. The cylindrical culture vessel is completely 	 One or more cell types may optionally be labeled with a
filled with a culture medium to eliminate head space. The 	 cell-tracking marker, such as a fluorescent cell-tracking dye,
cylindrical culture vessel rotates about a substantially central 40 prior to their introduction into the cylindrical culture vessel.
horizontal axis. The resulting substantially horizontal rota- 	 In this way, it is possible to determine the location of the
tion occurs at a rate chosen so that (1) there is essentially no 	 individual cell types during, or at the conclusion of, the for-
relative motion between the walls of the vessel and the culture 	 mation of the bone constructs. For example, fluorescent Cell-
medium; and (2) cells remain in suspension within a deter- 	 Tracker dyes, available from Invitrogen, Inc., may be used in
mined spatial region of the vessel such that they experience a 45 conjunction with fluorescence microscopy techniques, such
continuous "free fall' through the culture medium at terminal 	 as confocal fluorescence microscopy. If more than one cell
velocity with low shear stress and low turbulence. This free	 type is labeled, then they are labeled with different colored
fall state may be maintained continuously for up to several
	
dyes so that each cell type can be tracked independently.
months in some applications described in the prior art. The 	 Cells are then cultured in the matrix-free culture medium in
continuous orbital movement of the medium relative to the 50 the cylindrical culture vessel during substantially horizontal
cells also allows for highly efficient transfer of gases and	 rotation to form aggregates of the two cell types. The rate of
nutrients.	 substantially horizontal rotation during the aggregation phase
In some embodiments, the diameter of the cylindrical cul- 	 is chosen so that both (1) low shear conditions are obtained;
ture vessel is substantially greater than its height. Such cylin-	 and (2) the osteoclast precursors and the osteoblasts are able
drical culture vessels are often referred to in the art as High 55 to coalesce and form aggregates. The rate of substantially
Aspect Ratio Vessels (HARVs). For example, a HARV having	 horizontal rotation may be selected by monitoring the cylin-
• volume of 10 mL may have a diameter of about 10 cm and
	
drical culture vessel and by monitoring the cells and aggre-
• height of about 1 cm. At least a portion of the vessel walls 	 gates in the cylindrical culture vessel (for example using
may be comprised of a gas permeable membrane to allow gas 	 microscopy), to insure that the cells and aggregates are not
exchange between the culture medium and the surrounding 60 sedimenting (which may be caused by too low a rate of
incubator environment. A suitable HARV is described in, for 	 rotation) or experiencing mechanical or excessive hydrody-
example, U.S. Pat. No. 5,437,998, incorporated by reference 	 namic shear stress. In embodiments in which a HARV is used,
herein in its entirety. One commercial embodiment of a 	 osteoclast precursors and osteoblasts may form a "boundary"
HARV is the Rotating Cell Culture System (RCCS) available	 layer situated in the middle of the HARV during the aggre-
from Synthecon, Inc.	 65 gation phase.
In some embodiments, the diameter of the cylindrical cul- 	 Preferably, the rate of substantially horizontal rotation dur-
ture vessel is substantially smaller than its height. Such cylin- 	 ing the aggregation phase is lower than the rate typically used
US 8,076,136 B2
7
for culturing cells. For example, in embodiments where the
cylindrical culture vessel is a 10 mL HARV having a diameter
of about 10 cm and a height of about 1 cm, substantially
horizontal rotation at less than about 14 revolutions per
minute (rpm) may be used. More preferably, substantially
horizontal rotation at less than about 12 rpm is used. In certain
preferred embodiments, substantially horizontal rotation at
between about 1 rpm and about 4 rpm is used. In one specific
embodiment, substantially horizontal rotation at about 2 rpm
is used. Note that the aforementioned rpm values are provided
with reference to a 10 mL HARV having the aforementioned
dimensions. The rpm values will vary depending on the vol-
ume and dimensions of the cylindrical culture vessel. The rpm
values during the aggregation phase for all such vessels are
easily determined using the aforementioned methodology.
Without being bound by a particular theory or mechanism,
it is believed that the use of a matrix-free culture medium
allows the use of rates of rotation that are substantially lower
than previously reported in the art for culturing mammalian
cells in a low shear stress rotating bioreactor. The use of low
rotation rates, in turn, is believed for the first time to promote
efficient association of osteoclast precursors and osteoblasts
into aggregates, and to promote three-dimensional organiza-
tion of these two cell types within the aggregates. Thus, the
organization of the cell types within the aggregate is not
constrained or influenced by an exogenous carrier material,
but rather by native cell-cell interaction. Consequently, the
three-dimensional organization of the osteoblasts and osteo-
clasts is physiologically realistic.
The rate of substantially horizontal rotation may optionally
be adjusted periodically during the aggregation phase in order
to compensate for the increase in the sedimentation velocity
(which is a function of volume and density) of the forming
aggregates, thereby maintaining the aggregates in low shear
"free fall" and preventing impact with the vessel wall.
The aggregation phase proceeds for a period of time suffi-
cient to produce the desired size of aggregates. Aggregate
formation may be monitored during the aggregation phase by
visual inspection, including through the use of microscopy. It
will be apparent from the disclosure that the size of the aggre-
gates is also dependent on the number of cells that are initially
introduced into the cylindrical culture vessel, the length of
time allowed for aggregation, as well as the rotation rate. In
one example, the aggregation phase is allowed to proceed for
between about 24 hours and about 48 hours.
Once aggregates of the desired size have formed, the aggre-
gates are preferably further cultured in the cylindrical culture
vessel during substantially horizontal rotation for a period of
time sufficient to allow the aggregates to grow to a desired
size through cell proliferation and/or to allow the osteoclast
precursors in the aggregates to differentiate into osteoclasts.
For example, the further culturing of the aggregates may
proceed for between about 5 and about 7 days and may lead to
grown aggregates having a diameter from between about 200
µm and about 4 mm. The resultant aggregates are sometimes
referred to herein as "spheroids." Preferably, the rate of sub-
stantially horizontal rotation during the further culturing is
higher than the rate during the aggregation phase, but still
provides low shear conditions in the cylindrical culture ves-
sel. For example, a rotation rate of between about 9 rpm and
about 16 rpm, preferably about 14 rpm, may be used during
further culturing for the 10 mL HARV exemplified above.
The rate of substantially horizontal rotation may optionally
be adjusted periodically during the further culturing phase in
order to compensate for the increase in the sedimentation
pathway of the aggregates as they grow in size (and hence
8
undergo changes in volume and density), thereby maintaining
the growing aggregates in low shear "free fall' and preventing
impact with the vessel wall.
Once aggregates have attained a desired size, a matrix-free
5 mineralization culture medium is introduced into the cylin-
drical culture vessel and the aggregates are cultured during
substantially horizontal rotation until they become mineral-
ized, thereby forming the mineralized three-dimensional
bone constructs of the disclosure. For example, the mineral-
io ization process may proceed for between about 7 days and
about 21 days. Preferably, the rate of substantially horizontal
rotation during such the mineralization process is higher than
the rate during the aggregation phase, but still provides low
shear conditions in the cylindrical culture vessel. For
15 example, a rotation rate of between about 9 rpm and about 20
rpm, preferably about 14 rpm, may be used during the min-
eralization phase for the 10 mL HARV exemplified above.
The rate of substantially horizontal rotation may optionally
be adjusted periodically during the mineralization phase in
20 order to compensate for the increase in the sedimentation
pathway of the aggregates as they increase in mass, thereby
maintaining the mineralizing aggregates in low shear "free
fall' and preventing impact with the vessel walls.
Mineralized three-dimensional bone constructs are har-
25 vested once they have achieved the desired size and mass. In
cylindrical culture vessels with one or more access ports, the
bone constructs are removed through a part. When the bone
constructs exceed the diameter of the port, the vessel is dis-
assembled to remove the bone constructs.
30 Osteoclasts and osteoblasts act coordinately in the miner-
alization process that occurs in vivo during bone formation
and bone restructuring. Accordingly, the mineralized three-
dimensional bone constructs of the disclosure, formed by the
coordinated activity of osteoblasts and osteoclasts, are physi-
35 ologically realistic.
As described above, the mineralized three-dimensional
bone constructs of the disclosure mimic trabecular bone in
many important aspects. The bone constructs of the disclo-
sure therefore have a great many uses in the fields of, for
40 example, physiology research and development, pharmaceu-
tical research, and orthopedics. Without limitation, these
include the direct benefit of developing a model for studying
both normal bone physiology and the pathological responses
observed in disease states such as osteoporosis, as well as
45 providing a highly economical platform for drug develop-
ment as it relates to the treatment of bone diseases.
The bone constructs of the disclosure also can be used for
autologous grafts. Specifically, diseased or missing bone may
be replaced with ex-vivo-derived mineralized three-dimen-
50 sional bone constructs in which the component osteoclasts
and osteoblasts are harvested from healthy bone and periph-
eral blood lymphocytes of the patient requiring the bone graft.
Examples of pathologies where the bone constructs of the
disclosure have therapeutic utility include fractures, non-
55 unions of fractures, congenital deformities of bone, bone
infections, bone loss, segmental bone defects, bone tumors,
metabolic and endocrine disorders affecting bone, and tooth
loss.
The bone constructs of the disclosure can also be used for
6o allogenic (allograft) grafts. Specifically, diseased or missing
bone can be replaced with ex vivo-derived mineralized three-
dimensional bone constructs in which the component osteo-
clasts and osteoblasts are harvested from healthy bone and
peripheral blood lymphocytes of another donor for the benefit
65 of a patient requiring bone graft. Examples of pathologies
where the bone constructs of the disclosure have therapeutic
utility include fractures, non-unions of fractures, congenital
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deformities of bone, bone infections, bone loss, segmental
bone defects, bone tumors, metabolic and endocrine disor-
ders affecting bone, and tooth loss.
Because the bone constructs of the disclosure closely
resemble bone formed in vivo, it is expected that they produce
unique factors and/or cytokines essential for bone remodel-
ing. Accordingly, the bone constructs of the disclosure serve
as a source for identification and harvesting of these factors.
The bone constructs of the disclosure may also be used to
study the interface between prosthetic devices/materials and
bone tissue.
Sensors or stimulation devices may be incorporated into
the bone constructs of the disclosure, and the resulting con-
structs implanted into bone tissue in vivo.
The bone constructs of the disclosure also may be used in
the production of large structures of specific dimensions for
"form-fitted" applications such as replacement of large
regions of the skeleton. This may be achieved using a com-
bination of tissue scaffolding/synthetic support materials
embedded with numerous bone constructs to generate a much
larger composite tissue aggregate.
The bone constructs of the disclosure also provide a low
cost alternative in which to study the effects of microgravity,
and of other space environment insults, such as radiation, on
the process of bone formation/bone loss.
The following examples are not to be construed as limiting
the scope of the invention disclosed herein in any way.
EXAMPLES
Example 1
Flow Chart of a Method For Producing Bone
Constructs
A flow chart of the method for producing mineralized
three-dimensional bone constructs is provided in FIG. 1.
Osteoblast and osteoclast precursor cells are first isolated
(110) from a healthy patient and then inoculated (120) into a
modified High Aspect Rotating Vessel (HARV) with a
matrix-free culture medium. Cells are allowed to aggregate
(130) at a rotation speed (typically 2 rpm) much lower than
that commonly used for the culture of mammalian cells. Low
speed promotes aggregation of the two or more cell types in
the early stages of aggregate formation. After the aggregation
period is over, the rotation speed of the High Aspect Rotating
Vessel is increased (140). This allows the bone construct to
grow into spheroids (150) in a state of "free fall". The min-
eralization step (160) is then initiated by exchanging the
initial matrix-free culture medium for a matrix-free mineral-
ization culture medium, which initiates the production of a
calcified crystalline matrix in the center of the tissue aggre-
gate. The bone constructs are then characterized. The spatial
arrangement of the different cell types is observed by confo-
cal microscopy imaging (170). The cells are visualized with
Z-series confocal imaging (175) by pre-labeling the initial
cell constituents of the construct with green fluorescent cell
tracker probe. The presence of calcium, phosphate and car-
bonate is revealed by using Alizarin red S stain and Kossa
histochernical stain (180), while the presence of nucleated
cells embedded in the crystalline matrix is revealed by
nuclear staining (185). Immuno-staining of the construct
(190) shows that cell markers such as alkaline phosphate are
absent from the cells embedded in the crystalline matrix.
Finally, prelabeling of the osteoclast precursor cells with Cell
Tracker-Orange (195) shows that precursor cells allowed to
10
aggregate and organize under these culture conditions
express the osteoclast differentiation marker, namely osteo-
calcein.
5	 Example 2
Production of Bone Constructs In A HARV
Cryopreserved primary normal human osteoblast cells and
io normal human osteoclast precursor cells were purchased
from the Cambrex Corporation (East Rutherford, N.7.) and
stored frozen under liquid nitrogen until needed.
Osteoblast cells were rapidly thawed by placing the vial in
a 37° C. oven, removing the cell suspension from the vial and
15 placing it in a 15 ml centrifugation tube and then diluting the
cell suspension with 10 ml of Dulbecco's Modified Essential
Medium (DMEM) supplemented with 10% (v/v) fetal bovine
serum (10% FBS-DMEM). The cells were then collected by
centrifugation at l 00xg for 5 min at 4° C. The supernatant was
20 then removed and the cell pellet was resuspended by gentle
tituration in 10 ml of fresh 10% FBS-DMEM supplemented
with 5 µM ascorbic acid and 1 mg/ml GA-1000 (gentamicin/
amphotericin B mixture). This process was carried out to
wash away the cryopreservatives in which the osteoblast cells
25 had been frozen.
The resulting cell suspension was then inoculated into a
T-75 tissue culture flask and incubated at 37° C. in a 5% COz
atmosphere tissue culture incubator for a total period of seven
days, with the medium being exchanged every three days.
3o After seven days the osteoblast culture was approaching con-
fluence and the osteoblast cells were harvested by removing
the cells from the surface of the flask using trypsin/EDTA
digestion followed by collection of the cells by centrifugation
as above. The cell pellet was then gently resuspended in 20 ml
35 of fresh 10% FBS-DMEM supplemented with 5 µM ascorbic
acid and 1 mg/ml GA-1000. The resulting cell suspension
was then inoculated into two T-75 tissue culture flasks and
again cultured for an additional seven days. This process of
osteoblast cell expansion continued until the cells had
4o reached passage 5 (i.e. five expansion/population doubling
cycles).
When the osteoblast cells had reached Passage 5 in culture
they were harvested using trypsin/EDTA digestion followed
by collection of the cells by centrifugation as above. The cell
45 pellet was then gently resuspended in 10 ml of fresh 10%
FBS-DMEM supplemented with 5 µM ascorbic acid, 100
U/ml penicillin and 100 ug/ml streptomycin, penicillin/strep-
tomycin being substituted for GA-1000 at this point due to the
potential negative effects of gentamicin on the capability of
50 osteoblast cells to produce mineralized extracellular matrix.
The resulting osteoblast cell suspension was counted using a
hemacytometer to ascertain the number of osteoblast cells/
ml. An aliquot of cell suspension containing a total of six
million osteoblast cells was removed and placed in a separate
55 15 ml centrifugation tube in preparation for the addition of
osteoclast precursor cells.
Osteoclast precursor cells were rapidly thawed by placing
the vial in a 37° C. oven, removing the cell suspension from
the vial and placing it in a 15 ml centrifugation tube and then
6o diluting the cell suspension with 10 ml of Dulbecco's Modi-
fied Essential Medium (DMEM) supplemented with 10%
(v/v) fetal bovine serum (10% FBS-DMEM). The cells were
then collected by centrifugation at 100xg for 5 min at 4° C.
The supernatant was then removed and the cell pellet was
65 resuspended by gentle tituration in 1 ml of fresh 10% FBS-
DMEM supplemented with 5 µM ascorbic acid, 100 U/ml
penicillin and 100 ug/ml streptomycin. This process was car-
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ried out to wash away the cryopreservatives in which the
osteoclast cells had been frozen.
The resulting osteoclast precursor cell suspension was
counted using a hemacytometer to ascertain the number of
osteoclast precursor cells/ml. An aliquot of cell suspension
containing a total of two million osteoclast cells was removed
and added to the 15 ml centrifuge tube containing the six
million osteoblast cells. The volume of medium in the cen-
trifuge tube was then was adjusted to a total of 10 ml by the
addition of fresh 10% FBS-DMEM supplemented with 5 µM
ascorbic acid, 100 U/ml penicillin and 100 ug/ml streptomy-
cin. Finally, the 10 ml of medium containing both osteoblast
and osteoclast cells was supplemented with 50 ng/ml mac-
rophage colony stimulating factor (M-CSF) and 50 ng/ml of
receptor activator of NF-kB (RANK) ligand.
The resulting osteoblast/osteoclast cell suspension was
then inoculated into a 10 ml rotating cell culture system
(RCCS) flask (also know as a High Aspect Ratio Vessel
HARV) (Synthecon, Inc.) and horizontally rotated at 2 RPM
for a period of 24 hr to allow coalescence of the osteoblast and
osteoclast cells into a solid, three dimensional tissue con-
struct. After a period of 24 hr, the rotation speed of the HARV
was increased to 14 RPM in order ensure that the tissue
construct was maintained in an optimal position within the
HARV, namely not touching or hitting the sides of the rotating
HARV rather in a state of "free-fall" within the medium
contained within the rotating HARV. The cell medium within
the HARV was exchanged with 10 ml of fresh 10% FBS-
DMEM supplemented with 5 µM ascorbic acid, 100 U/ml
penicillin, 100 ug/ml streptomycin, 50 ng/ml macrophage
colony stimulating factor (M-CSF) and 50 ng/ml of receptor
activator of NF-kB (RANK) ligand (a matrix-free culture
medium) after every fourth day of culture.
After a period of seven days of culture in the HARV under
the above conditions the medium was exchanged for 10 ml of
fresh 10% FBS-DMEM supplemented with 5 µM ascorbic
acid, 100 U/ml penicillin, 100 ug/ml streptomycin, 50 ng/ml
macrophage colony stimulating factor (M-CSF), 50 ng/ml of
receptor activator of NF-kB (RANK) ligand, 200 µM hydro-
cortisone-21-hemisuccinate and 10 mM beta-glycerophos-
phate (a matrix-free mineralization culture medium). The
hydrocortisone-21-hemisuccinate and beta-glycerophos-
phate were added to the medium to induce mineralization of
the tissue construct by the osteoblasts. The cell medium
within the HARV was exchanged with 10 ml of fresh 10%
FBS-DMEM supplemented with 5 µM ascorbic acid, 100
U/ml penicillin, 100 ug/ml streptomycin, 50 ng/ml macroph-
age colony stimulating factor (M-CSF), 50 ng/ml of receptor
activator of NF-kB (RANK) ligand, 200 µM hydrocortisone-
21-hemisuccinate and 10 mM beta-glycerophosphate every
fourth day until the tissue construct was harvested.
Example 3
Imaging of Bone Constructs
The method of Example 2 was followed, with the following
differences: primary osteoblasts and osteoclast precursors
were mixed together at about a 2:1 ratio of osteoblasts to
osteoclast precursors, with the total number of cells being
about 9 million cells; the mixture of cells was then horizon-
tally rotated at 2 rpm for 48 hrs, and then at 14 rpm for 5 days;
and mineralization proceeded at 16 rpm for 21 days. The
resulting mineralized three-dimensional bone constructs are
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pictured in FIG. 2A (at 14 days of mineralization) and FIG.
2B (at 21 days of mineralization). The scale bar in each figure
is 1 cm.
5	 Example 4
Bone Constructs With Labeled Osteoclasts
The method of Example 2 was followed, withthe following
10 differences: osteoclast precursors were labeled with the fluo-
rescent CellTracker-Red probe (Invitrogen, Inc.) prior to mix-
ing with osteoblasts; primary osteoblasts and labeled osteo-
clast precursors were mixed together at about a 2:1 ratio of
osteoblasts to osteoclast precursors, with the total number of
15 cells being about 3 million cells; the mixture of cells was then
horizontally rotated at 2 rpm for 24 hrs, and then at 14 rpm for
5 days; and mineralization proceeded at 16 rpm for 14 days.
FIG. 3A shows a fluorescence confocal microscopy image of
an optical section through some of the resulting mineralized
20 three-dimensional bone constructs. The results show that
osteoclast precursor cells (observable as white spots in FIG.
3A) have spatially arranged themselves as an outer layer of
the mineralized three-dimensional bone constructs with the
putative osteoblast cells being embedded in the crystalline
25 matrix of the central region of the constructs. FIG. 3B shows
the same constructs viewed in incident laser light (i.e. non-
fluorescent illumination) to illustrate the shape of the con-
structs. The scale bar in each of FIG. 3A and FIG. 3B is 200
µm.
30
Example 5
Optic Sectioning of a Bone Construct With Labeled
Osteoclasts
35
The method of Example 2 was followed, withthe following
differences: osteoclast precursors were labeled with the fluo-
rescent CellTracker-Green probe (Invitrogen, Inc.) prior to
mixing with osteoblasts; primary osteoblasts and labeled
40 osteoclast precursors were mixed together at about a 2:1 ratio
of osteoblasts to osteoclast precursors, with the total number
of cells being about 6 million cells; the mixture of cells was
then horizontally rotated at 2 rpm for 48 hrs, and then at 14
rpm for 5 days; and mineralization proceeded at 16 rpm for 21
45 days. Three dimensional reconstruction of a resulting large
bone construct was performed using Z series confocal imag-
ing. Panels A-I in FIG. 4 are the individual images used by the
confocal imaging software to build the optical reconstruction
of the bone construct in three dimensions, each image repre-
50 senting a sequential view over the surface of the construct
(white spots indicate individual cells). FIG. 4 indicates that
the arrangement of osteoclasts to the outer layer of the con-
struct remains a feature of the construct even after extended
culture periods (i.e. a total of four weeks in the HARV vessel,
55 including three weeks grown in mineralization conditions).
Labeled osteoclasts are apparent in an outer layer covering
the surface of the construct.
Example 6
60
Staining of Bone Constructs With Alizarin Red S,
von Kossa, and Harris Hematoxylin Stains
Mineralized three-dimensional bone constructs were pre-
65 pared as detailed in Example 3. The bone constructs were then
fixed using a Bouin's solution (a rapid penetrating fixative
solution), frozen sectioned, and stained for calcium using the
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Alizarin red S stain and for phosphates and carbonates using
the von Kossa histochemical stain. FIG. 5A shows a 5x mag-
nification image ofAlizarin red S staining and FIG. 5B shows
a 20x magnification image of Alizarin red S staining (which
appears as the dark regions of the images). FIG. 5C shows a
5x magnification image of von Kossa staining and FIG. 5B
shows a 20x magnification image of von Kossa staining
(which appears as the dark regions of the images). The results
demonstrate that the crystalline matrix of the mineralized
three-dimensional bone constructs contain mineral elements
observed in normal human bone in vivo.
The same sections were also stained for the presence of
nucleated cells using the Harris Hematoxylin stain. The
results are shown in FIG. 6A (5x magnification image) and
FIG. 6B (20x magnification image). The dark regions of the
image indicate staining. The staining pattern illustrates a
large number of cells embedded within the crystalline matrix
of the three dimensional construct. These cell nuclei appear
intact with little or no signs of nuclear fragmentation, a his-
tological indicator of the occurrence of cell death/apoptosis.
Arrows in FIG. 6B point to large numbers of cells embedded
within the crystalline matrix in the three dimensional con-
struct. Cell nuclei appear intact with little or no signs of
nuclear fragmentation; such fragmentation would be a histo-
logical indicator of the occurrence of cell death/apoptosis.
Immuno-staining of these sections for the presence of osteo-
blast cell markers, such as alkaline pho sphatase, indicated the
absence of osteoblast cell markers in the cell type embedded
in the crystalline matrix. Thus, it is believed that the cells
embedded in the crystalline matrix are osteocytes.
Example 7
Detection of Osteocalcein, An Osteoclast
Differentiation Marker, In Bone Constructs Using
Immunofluorescence
The method of Example 2 was followed, with the following
differences: osteoclast precursors were labeled with the fluo-
rescent CellTracker-Orange probe (Invitrogen, Inc.) prior to
mixing with osteoblasts; primary osteoblasts and labeled
osteoclast precursors were mixed together at about a 2:1 ratio
of osteoblasts to osteoclast precursors, with the total number
of cells being about 6 million cells; the mixture of cells was
then horizontally rotated at 2 rpm for 48 hrs, and then at 14
rpm for 5 days; and mineralization proceeded at 16 rpm for 21
days. The resulting mineralized three-dimensional bone con-
structs were fixed using a phosphate buffered saline solution
(pH 7.2) containing 1% (v/v) freshly generated formalde-
hyde. The fixed bone constructs were then immunochemi-
cally stained using a monoclonal antibody against osteocal-
cein (an osteoclast differentiation marker) as the primary
antibody and an Alexa 488-labeled secondary antibody. FIG.
7A-7C shows images obtained by simultaneously imaging
both markers in one of the bone constructs using confocal
microscopy. Specifically, FIG. 7A shows osteocalcein stain-
ing, FIG. 7B shows Celffracker-Orange staining, and FIG.
7C shows the same construct illuminated with incident laser
light. The results indicate that osteocalcein staining and Cell-
Tracker-Orange staining (both visible as a white "ring"
around the construct in FIGS. 7A and 713) are spatially local-
ized to the same area of the construct. This indicates that the
osteoclast precursor cells had differentiated into mature
osteoclasts that were spatially localized to the surface of the
construct.
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What is claimed is:
1. A method for promoting formation of a three-dimen-
sional osteogenic cell aggregate ex vivo, the method compris-
ing:
5 (a) introducing osteoclast precursors and osteoblasts into a
cylindrical culture vessel that rotates about a central
horizontal axis,
wherein said cylindrical culture vessel contains a matrix-
free culture medium, wherein the matrix-free culture
10 medium does not comprise an exogenous scaffolding
material that guides formation of the three-dimensional
osteogenic cell aggregate,
(b) co-culturing said osteoblasts and said osteoclast pre-
cursors in said cylindrical culture vessel during horizon-
tal rotation at a rate of between 1 and 2 rotations per
15 minute to promote scaffold-free interaction, aggregation
and organization of said osteoclast precursors and said
osteoblasts until the three dimensional tissue constructs
are formed,
(c) further culturing, the tome dimensional aggregate of
20 step (b) in a matrix-free mineralization culture medium
in said cylindrical culture vessel at a higher average rate
of horizontal rotation than the average rate of horizontal
rotation during step (b) to increase perfusion and thereby
to form mature three dimensional mineralized osteo-
25	 genic cell aggregate composed of osteoblasts and osteo-
clasts differentiated from osteoclast precursors,
wherein mineralized three dimensional osteogenic cell
aggregate comprise an outer zone comprising osteo-
clasts surrounding an inner porous core comprising
30	 osteoblasts and/or osteocytes encased in a mineralized
extracellular matrix.
2. The method of claim 1, wherein said cylindrical culture
vessel is a High Aspect Ratio Vessel (HARV) having a diam-
eter greater than its height
35 3. The method of claim 1 wherein the ratio of osteoblasts:
osteoclast precursors introduced into said cylindrical culture
vessel in step (a) is between about 2:1 and about 3:1.
4. The method of claim 3 wherein between about 1 million
and about 8 million osteoblasts are introduced into said cylin-
4o drical culture vessel in step (a).
5. The method of claim 1 wherein rate of horizontal rota-
tion of said cylindrical culture vessel is periodically adjusted
during step (c) to counteract changes in the sedimentation
velocity of said aggregates.
45	 6. The method of claim 1, wherein step (b) is allowed to
proceed for between about 5 days and about 7 days.
7. The method of claim 1. wherein step (c) is allowed to
proceed for between about 7 days and about 21 days.
8. The method of claim 1, wherein said cylindrical culture
50 vessel has a diameter of about 10 cm and a height of about 1
cm, and wherein the higher average rate of horizontal rotation
than the average rate of horizontal rotation during step (b) is
between about 9 revolutions per minute and about 16 revolu-
tions per minute.
55 9. The method of claim 1, wherein the size of each three
dimensional osteogenic cell aggregate in step (b) is between
about 200 µm and about 4 mm in diameter.
10. The method according to claim 1, wherein the matrix-
free culture medium of step (a) comprises at least one osteo-
6o blast differentiation factor and at least one osteoclast differ-
entiation factor.
11. The method of claim 10, wherein said at least one
osteoclast differentiation factor comprises Receptor Activa-
tor of NF-KB ligand and Macrophage Colony Stimulating
65 Factor.
12. The method of claim 10, wherein the at least one
osteoblast differentiation factor comprises ascorbic acid.
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	13. The method according to claim 1, wherein the matrix- 	 14. The method of claim 13, wherein said at least one
	
free mineralization culture medium of step (c) comprises at 	 osteoblast mineralization factor comprises beta-glycerophos-
	
least one osteoblast differentiation factor and at least one 	 phate and hydrocortisone-21-hemisuccinate.
osteoclast differentiation factor and at least one osteoblast
mineralization factor.
